Research Articles | Page 4 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

Research Articles

  1. Home
  2. Research

Compiled for your convenience are articles on bone marrow failure research and treatment from the world’s major journals on hematology / oncology.

Article Title Original Publication Date Journal Bone Marrow Disease
HLA-haploidentical stem cell transplantation in children with inherited bone marrow failure syndromes: A retrospective analysis on behalf of EBMT severe aplastic Anemia and pediatric diseases working parties Jun 2024 American Journal of Hematology Aplastic Anemia
Alemtuzumab in relapsed immune severe aplastic anemia: Long-term results of a phase II study Apr 2023 American Journal of Hematology Aplastic Anemia
A growing panoply of options for patients with paroxysmal nocturnal hemoglobinuria Sep 2024 American Journal of Hematology Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria Sep 2024 American Journal of Hematology Paroxysmal Nocturnal Hemoglobinuria (PNH)
Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T) - "2021 update on diagnosis, risk-stratification, and management" Jan 2021 American Journal of Hematology Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN)
Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition Sep 2024 American Journal of Hematology Paroxysmal Nocturnal Hemoglobinuria (PNH)
Distinct and convergent consequences of splice factor mutations in myelodysplastic syndromes Nov 2019 American Journal of Hematology Myelodysplastic Syndromes (MDS)
Luspatercept use for lower risk myelodysplastic syndromes: Active but not enough Jun 2023 American Journal of Hematology Myelodysplastic Syndromes (MDS)
Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria Jun 2024 American Journal of Hematology Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition Jun 2024 American Journal of Hematology Paroxysmal Nocturnal Hemoglobinuria (PNH)